-
1
-
-
22844448780
-
Hypertension in adults across the age spectrum: Current outcomes and control in the community
-
Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-72.
-
(2005)
JAMA
, vol.294
, pp. 466-472
-
-
Lloyd-Jones, D.M.1
Evans, J.C.2
Levy, D.3
-
2
-
-
9144248446
-
Hypertension treatment and control in five European countries, Canada, and the United States
-
Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7.
-
(2004)
Hypertension
, vol.43
, pp. 10-17
-
-
Wolf-Maier, K.1
Cooper, R.S.2
Kramer, H.3
-
3
-
-
0038460302
-
The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report
-
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
4
-
-
0023786331
-
Molecular biology of the reninangiotensin system
-
Dzau VJ, Burt DW, Pratt RE. Molecular biology of the reninangiotensin system. Am J Physiol 1988; 255: F563-73.
-
(1988)
Am J Physiol
, vol.255
-
-
Dzau, V.J.1
Burt, D.W.2
Pratt, R.E.3
-
5
-
-
0036535405
-
The angiotensin-converting enzyme gene family: Genomics and pharmacology
-
Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-83.
-
(2002)
Trends Pharmacol Sci
, vol.23
, pp. 177-183
-
-
Turner, A.J.1
Hooper, N.M.2
-
6
-
-
0037834636
-
Angiotensin receptors: Distribution, signalling and function
-
Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond) 2001; 100: 481-92.
-
(2001)
Clin Sci (Lond)
, vol.100
, pp. 481-492
-
-
Dinh, D.T.1
Frauman, A.G.2
Johnston, C.I.3
Fabiani, M.E.4
-
7
-
-
0026069821
-
Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia
-
Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18: II100-5.
-
(1991)
Hypertension
, vol.18
-
-
Dzau, V.J.1
Gibbons, G.H.2
Pratt, R.E.3
-
8
-
-
0027160183
-
Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II
-
Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-74.
-
(1993)
J Clin Invest
, vol.91
, pp. 2268-2274
-
-
Itoh, H.1
Mukoyama, M.2
Pratt, R.E.3
Gibbons, G.H.4
Dzau, V.J.5
-
9
-
-
0035573901
-
Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: A possible role for interleukin-6
-
Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 2001; 21: 1464-9.
-
(2001)
Arterioscler Thromb Vasc Biol
, vol.21
, pp. 1464-1469
-
-
Keidar, S.1
Heinrich, R.2
Kaplan, M.3
Hayek, T.4
Aviram, M.5
-
10
-
-
0027968595
-
Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme
-
Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94: 978-84.
-
(1994)
J Clin Invest
, vol.94
, pp. 978-984
-
-
Morishita, R.1
Gibbons, G.H.2
Ellison, K.E.3
-
11
-
-
0031811033
-
Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure
-
Su EJ, Lombardi DM, Siegal J, Schwartz SM. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998; 31: 1331-7.
-
(1998)
Hypertension
, vol.31
, pp. 1331-1337
-
-
Su, E.J.1
Lombardi, D.M.2
Siegal, J.3
Schwartz, S.M.4
-
12
-
-
0030807119
-
Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells
-
Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-95.
-
(1997)
Thromb Haemost
, vol.77
, pp. 1189-1195
-
-
Nishimura, H.1
Tsuji, H.2
Masuda, H.3
-
13
-
-
33646792585
-
Renal and vascular hypertension-induced inflammation: Role of angiotensin II
-
Ruiz-Ortega M, Esteban V, Ruperez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15: 159-66.
-
(2006)
Curr Opin Nephrol Hypertens
, vol.15
, pp. 159-166
-
-
Ruiz-Ortega, M.1
Esteban, V.2
Ruperez, M.3
-
14
-
-
0034024638
-
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
-
Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35: 985-91.
-
(2000)
Hypertension
, vol.35
, pp. 985-991
-
-
Mazzolai, L.1
Pedrazzini, T.2
Nicoud, F.3
Gabbiani, G.4
Brunner, H.R.5
Nussberger, J.6
-
15
-
-
1542374750
-
Evidence for a local angiotensingenerating system and dose-dependent inhibition of glucosestimulated insulin release by angiotensin II in isolated pancreatic islets
-
Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensingenerating system and dose-dependent inhibition of glucosestimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.
-
(2004)
Diabetologia
, vol.47
, pp. 240-248
-
-
Lau, T.1
Carlsson, P.O.2
Leung, P.S.3
-
17
-
-
58549083401
-
Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors
-
Ognibene DT, Oliveira PR, Marins de Carvalho LC, et al. Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors. Clin Exp Pharmacol Physiol 2009; 36: 12-9.
-
(2009)
Clin Exp Pharmacol Physiol
, vol.36
, pp. 12-19
-
-
Ognibene, D.T.1
Oliveira, P.R.2
Marins de Carvalho, L.C.3
-
18
-
-
36348982705
-
Emerging concepts of regulation of angiotensin II receptors: New players and targets for traditional receptors
-
Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007; 27: 2532-9.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 2532-2539
-
-
Mogi, M.1
Iwai, M.2
Horiuchi, M.3
-
19
-
-
0034601761
-
Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice
-
Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000; 102: 1684-9.
-
(2000)
Circulation
, vol.102
, pp. 1684-1689
-
-
Akishita, M.1
Iwai, M.2
Wu, L.3
-
20
-
-
0035902572
-
Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension
-
Ichihara S, Senbonmatsu T, Price E, Jr., Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension. Circulation 2001; 104: 346-51.
-
(2001)
Circulation
, vol.104
, pp. 346-351
-
-
Ichihara, S.1
Senbonmatsu, T.2
Price Jr., E.3
Ichiki, T.4
Gaffney, F.A.5
Inagami, T.6
-
21
-
-
0034991812
-
Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications
-
Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001; 14: 98S-102S.
-
(2001)
Am J Hypertens
, vol.14
-
-
Carey, R.M.1
Jin, X.H.2
Siragy, H.M.3
-
22
-
-
0028010788
-
Tissue angiotensin system in cardiovascular medicine. A paradigm shift
-
Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493-8.
-
(1994)
Circulation
, vol.89
, pp. 493-498
-
-
Dzau, V.J.1
Re, R.2
-
23
-
-
0031149958
-
Cultured myofibroblasts generate angiotensin peptides de novo
-
Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997; 29: 1375-86.
-
(1997)
J Mol Cell Cardiol
, vol.29
, pp. 1375-1386
-
-
Katwa, L.C.1
Campbell, S.E.2
Tyagi, S.C.3
Lee, S.J.4
Cicila, G.T.5
Weber, K.T.6
-
24
-
-
0031736311
-
The renin-angiotensin system in the vessel wall
-
Muller DN, Luft FC. The renin-angiotensin system in the vessel wall. Basic Res Cardiol 1998; 93 (Suppl 2): 7-14.
-
(1998)
Basic Res Cardiol
, vol.93
, Issue.SUPPL. 2
, pp. 7-14
-
-
Muller, D.N.1
Luft, F.C.2
-
25
-
-
0023624502
-
Tissue renin-angiotensin system: Sites of angiotensin formation
-
Campbell DJ. Tissue renin-angiotensin system: sites of angiotensin formation. J Cardiovasc Pharmacol 1987; 10 (Suppl 7): S1-8.
-
(1987)
J Cardiovasc Pharmacol
, vol.10
, Issue.SUPPL. 7
-
-
Campbell, D.J.1
-
26
-
-
0023120913
-
Circulating and tissue angiotensin systems
-
Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
-
(1987)
J Clin Invest
, vol.79
, pp. 1-6
-
-
Campbell, D.J.1
-
27
-
-
0031016576
-
Myofibroblasts and local angiotensin II in rat cardiac tissue repair
-
Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 1997; 29: 31-42.
-
(1997)
Int J Biochem Cell Biol
, vol.29
, pp. 31-42
-
-
Weber, K.T.1
Sun, Y.2
Katwa, L.C.3
-
28
-
-
0028012543
-
Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence
-
von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-70.
-
(1994)
Circulation
, vol.89
, pp. 458-470
-
-
von Lutterotti, N.1
Catanzaro, D.F.2
Sealey, J.E.3
Laragh, J.H.4
-
29
-
-
42649088714
-
Renin and prorenin disappearance in humans post-nephrectomy: Evidence for binding?
-
Krop M, de Bruyn JH, Derkx FH, Danser AH. Renin and prorenin disappearance in humans post-nephrectomy: evidence for binding? Front Biosci 2008; 13: 3931-9.
-
(2008)
Front Biosci
, vol.13
, pp. 3931-3939
-
-
Krop, M.1
de Bruyn, J.H.2
Derkx, F.H.3
Danser, A.H.4
-
30
-
-
0025972262
-
Molecular biology of the vascular reninangiotensin system
-
Samani NJ, Swales JD. Molecular biology of the vascular reninangiotensin system. Blood Vessels 1991; 28: 210-6.
-
(1991)
Blood Vessels
, vol.28
, pp. 210-216
-
-
Samani, N.J.1
Swales, J.D.2
-
31
-
-
0036266596
-
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
-
Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-27.
-
(2002)
J Clin Invest
, vol.109
, pp. 1417-1427
-
-
Nguyen, G.1
Delarue, F.2
Burckle, C.3
Bouzhir, L.4
Giller, T.5
Sraer, J.D.6
-
32
-
-
0037591344
-
Human prorenin has gate and handle regions for its non-proteolytic activation
-
Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has gate and handle regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22.
-
(2003)
J Biol Chem
, vol.278
, pp. 22217-22
-
-
Suzuki, F.1
Hayakawa, M.2
Nakagawa, T.3
-
33
-
-
0035834247
-
The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
-
Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 1L-20L.
-
(2001)
Am J Cardiol
, vol.88
-
-
Dzau, V.J.1
Bernstein, K.2
Celermajer, D.3
-
34
-
-
33845608395
-
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein
-
Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-66.
-
(2006)
Circ Res
, vol.99
, pp. 1355-1366
-
-
Schefe, J.H.1
Menk, M.2
Reinemund, J.3
-
35
-
-
33750271641
-
The (pro)renin receptor: Therapeutic consequences
-
Nguyen G, Danser AH. The (pro)renin receptor: therapeutic consequences. Expert Opin Investig Drugs 2006; 15: 1131-5.
-
(2006)
Expert Opin Investig Drugs
, vol.15
, pp. 1131-1135
-
-
Nguyen, G.1
Danser, A.H.2
-
36
-
-
39749098706
-
Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide
-
Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-8.
-
(2008)
Hypertension
, vol.51
, pp. 682-688
-
-
Feldt, S.1
Batenburg, W.W.2
Mazak, I.3
-
37
-
-
33747050068
-
Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: Put the blame on the (pro)renin receptor?
-
Nguyen G. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? Kidney Int 2006; 70: 618-20.
-
(2006)
Kidney Int
, vol.70
, pp. 618-620
-
-
Nguyen, G.1
-
38
-
-
33646160993
-
Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension
-
Ichihara A, Kaneshiro Y, Takemitsu T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
-
(2006)
Hypertension
, vol.47
, pp. 894-900
-
-
Ichihara, A.1
Kaneshiro, Y.2
Takemitsu, T.3
-
40
-
-
62949147120
-
Diabetic complications: A role for the prorenin-(pro)renin receptor-TGF-beta1 axis?
-
van den Heuvel M, Batenburg WW, Danser AH. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis? Mol Cell Endocrinol 2009; 302: 213-8.
-
(2009)
Mol Cell Endocrinol
, vol.302
, pp. 213-218
-
-
van den Heuvel, M.1
Batenburg, W.W.2
Danser, A.H.3
-
41
-
-
0027508388
-
Non-angiotensin effects of angiotensinconverting enzyme inhibitors
-
Sunman W, Sever PS. Non-angiotensin effects of angiotensinconverting enzyme inhibitors. Clin Sci (Lond) 1993; 85: 661-70.
-
(1993)
Clin Sci (Lond)
, vol.85
, pp. 661-670
-
-
Sunman, W.1
Sever, P.S.2
-
43
-
-
0036452679
-
Angiotensin II inhibits renin gene transcription via the protein kinase C pathway
-
Muller MW, Todorov V, Kramer BK, Kurtz A. Angiotensin II inhibits renin gene transcription via the protein kinase C pathway. Pflugers Arch 2002; 444: 499-505.
-
(2002)
Pflugers Arch
, vol.444
, pp. 499-505
-
-
Muller, M.W.1
Todorov, V.2
Kramer, B.K.3
Kurtz, A.4
-
44
-
-
0028957020
-
Commentary: Renin assays: A debate for clinicians, not only for specialists
-
Menard J, Guyene TT. Commentary: renin assays: a debate for clinicians, not only for specialists. J Hypertens 1995; 13: 367-9.
-
(1995)
J Hypertens
, vol.13
, pp. 367-369
-
-
Menard, J.1
Guyene, T.T.2
-
45
-
-
0023885367
-
In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II
-
Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988; 42: 1683-8.
-
(1988)
Life Sci
, vol.42
, pp. 1683-1688
-
-
Nussberger, J.1
Brunner, D.B.2
Waeber, B.3
Brunner, H.R.4
-
46
-
-
0023786558
-
Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment
-
Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988; 12: 223-6.
-
(1988)
Hypertension
, vol.12
, pp. 223-226
-
-
Laragh, J.H.1
Lamport, B.2
Sealey, J.3
Alderman, M.H.4
-
47
-
-
0028278186
-
Pharmacology of renin inhibitors and their application to the treatment of hypertension
-
Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther 1994; 61: 325-44.
-
(1994)
Pharmacol Ther
, vol.61
, pp. 325-344
-
-
Wood, J.M.1
Cumin, F.2
Maibaum, J.3
-
48
-
-
0036372173
-
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril
-
Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-8.
-
(2002)
Hypertension
, vol.39
-
-
Nussberger, J.1
Wuerzner, G.2
Jensen, C.3
Brunner, H.R.4
-
49
-
-
0031015833
-
Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients
-
Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10: 1-8.
-
(1997)
Am J Hypertens
, vol.10
, pp. 1-8
-
-
Alderman, M.H.1
Ooi, W.L.2
Cohen, H.3
Madhavan, S.4
Sealey, J.E.5
Laragh, J.H.6
-
50
-
-
0029911431
-
Inappropriately high plasma renin activity accompanies chronic loss of renal function
-
Yeyati NL, Adrogue HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol 1996; 16: 471-7.
-
(1996)
Am J Nephrol
, vol.16
, pp. 471-477
-
-
Yeyati, N.L.1
Adrogue, H.J.2
-
51
-
-
0033862643
-
Plasma renin activity in the emergency department and its independent association with acute myocardial infarction
-
Blumenfeld JD, Sealey JE, Alderman MH, et al. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens 2000; 13: 855-63.
-
(2000)
Am J Hypertens
, vol.13
, pp. 855-863
-
-
Blumenfeld, J.D.1
Sealey, J.E.2
Alderman, M.H.3
-
52
-
-
34547726196
-
Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension
-
Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61: 1461-8.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 1461-1468
-
-
Nussberger, J.1
Gradman, A.H.2
Schmieder, R.E.3
Lins, R.L.4
Chiang, Y.5
Prescott, M.F.6
-
53
-
-
9644287897
-
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
-
Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-33.
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 3126-3133
-
-
Azizi, M.1
Menard, J.2
Bissery, A.3
-
54
-
-
0033995775
-
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
-
Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-6.
-
(2000)
Circulation
, vol.101
, pp. 844-846
-
-
Jorde, U.P.1
Ennezat, P.V.2
Lisker, J.3
-
55
-
-
28844457541
-
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition
-
van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106: 367-72.
-
(2006)
Int J Cardiol
, vol.106
, pp. 367-372
-
-
van de Wal, R.M.1
Plokker, H.W.2
Lok, D.J.3
-
56
-
-
0023571272
-
Effects of converting-enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: Correlation of chemical structure and biologic activity
-
Zusman RM. Effects of converting-enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987; 10: 13-23.
-
(1987)
Am J Kidney Dis
, vol.10
, pp. 13-23
-
-
Zusman, R.M.1
-
57
-
-
0033028679
-
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
-
MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 57-61.
-
(1999)
Heart
, vol.82
, pp. 57-61
-
-
Macfadyen, R.J.1
Lee, A.F.2
Morton, J.J.3
Pringle, S.D.4
Struthers, A.D.5
-
58
-
-
0030096265
-
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
-
Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 47-54.
-
(1996)
J Card Fail
, vol.2
, pp. 47-54
-
-
Struthers, A.D.1
-
59
-
-
34548163060
-
The incidence and implications of aldosterone breakthrough
-
Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-92.
-
(2007)
Nat Clin Pract Nephrol
, vol.3
, pp. 486-492
-
-
Bomback, A.S.1
Klemmer, P.J.2
-
60
-
-
0036314951
-
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats
-
Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
-
(2002)
Hypertension
, vol.40
, pp. 28-33
-
-
Naruse, M.1
Tanabe, A.2
Sato, A.3
-
61
-
-
34047231332
-
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution?
-
Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-35.
-
(2007)
Expert Opin Pharmacother
, vol.8
, pp. 529-535
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
Kakafika, A.I.3
Tziomalos, K.4
Karagiannis, A.5
-
62
-
-
0000586975
-
The preparation, purification, and amino acid sequence of a polypeptide renin substrate
-
Skeggs LT, Jr., Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439-53.
-
(1957)
J Exp Med
, vol.106
, pp. 439-453
-
-
Skeggs Jr., L.T.1
Kahn, J.R.2
Lentz, K.3
Shumway, N.P.4
-
63
-
-
0024433356
-
Renin inhibitors: Discovery and development. An overview and perspective
-
Kleinert HD. Renin inhibitors: discovery and development. An overview and perspective. Am J Hypertens 1989; 2: 800-8.
-
(1989)
Am J Hypertens
, vol.2
, pp. 800-808
-
-
Kleinert, H.D.1
-
65
-
-
0042661157
-
Structure-based design of aliskiren, a novel orally effective renin inhibitor
-
Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
-
(2003)
Biochem Biophys Res Commun
, vol.308
, pp. 698-705
-
-
Wood, J.M.1
Maibaum, J.2
Rahuel, J.3
-
66
-
-
43449133877
-
A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects
-
Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008; 46: 252-8.
-
(2008)
Int J Clin Pharmacol Ther
, vol.46
, pp. 252-258
-
-
Limoges, D.1
Dieterich, H.A.2
Yeh, C.M.3
Vaidyanathan, S.4
Howard, D.5
Dole, W.P.6
-
67
-
-
47049089844
-
Clinical pharmacokinetics and pharmacodynamics of aliskiren
-
Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008; 47: 515-31.
-
(2008)
Clin Pharmacokinet
, vol.47
, pp. 515-531
-
-
Vaidyanathan, S.1
Jarugula, V.2
Dieterich, H.A.3
Howard, D.4
Dole, W.P.5
-
68
-
-
33750357566
-
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
-
Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62: 690-8.
-
(2006)
Br J Clin Pharmacol
, vol.62
, pp. 690-698
-
-
Vaidyanathan, S.1
Jermany, J.2
Yeh, C.3
Bizot, M.N.4
Camisasca, R.5
-
69
-
-
33947543780
-
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects
-
Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47: 453-60.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 453-460
-
-
Vaidyanathan, S.1
Reynolds, C.2
Yeh, C.M.3
-
70
-
-
34547628374
-
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
-
Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46: 661-75.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 661-675
-
-
Vaidyanathan, S.1
Bigler, H.2
Yeh, C.3
-
71
-
-
33846456943
-
Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment
-
Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47: 192-200.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 192-200
-
-
Vaidyanathan, S.1
Warren, V.2
Yeh, C.3
Bizot, M.N.4
Dieterich, H.A.5
Dole, W.P.6
-
72
-
-
53349090037
-
Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
-
Huang HL, Vaidyanathan S, Yeh CM, et al. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med Res Opin 2008; 24: 2449-56.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 2449-2456
-
-
Huang, H.L.1
Vaidyanathan, S.2
Yeh, C.M.3
-
73
-
-
28044453329
-
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine
-
Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527-35.
-
(2005)
Int J Clin Pharmacol Ther
, vol.43
, pp. 527-535
-
-
Dieterle, W.1
Corynen, S.2
Vaidyanathan, S.3
Mann, J.4
-
74
-
-
54049086657
-
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren
-
Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48: 1323-38.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 1323-1338
-
-
Vaidyanathan, S.1
Camenisch, G.2
Schuetz, H.3
-
75
-
-
50149092635
-
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects
-
Vaidyanathan S, Maboudian M, Warren V, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008; 24: 2313-26.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 2313-2326
-
-
Vaidyanathan, S.1
Maboudian, M.2
Warren, V.3
-
76
-
-
34247141847
-
Aliskiren (Tekturna) for hypertension
-
Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49: 29-31.
-
(2007)
Med Lett Drugs Ther
, vol.49
, pp. 29-31
-
-
-
77
-
-
0347479295
-
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
-
Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
-
(2003)
Hypertension
, vol.42
, pp. 1137-1143
-
-
Stanton, A.1
Jensen, C.2
Nussberger, J.3
O'Brien, E.4
-
78
-
-
14844363404
-
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebolike tolerability in hypertensive patients
-
Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebolike tolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
-
(2005)
Circulation
, vol.111
, pp. 1012-1018
-
-
Gradman, A.H.1
Schmieder, R.E.2
Lins, R.L.3
Nussberger, J.4
Chiang, Y.5
Bedigian, M.P.6
-
79
-
-
34447521458
-
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
-
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9.
-
(2007)
Lancet
, vol.370
, pp. 221-229
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Fang, H.4
Zhang, J.5
Satlin, A.6
-
80
-
-
34548855067
-
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension
-
Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21: 780-7.
-
(2007)
J Hum Hypertens
, vol.21
, pp. 780-787
-
-
Strasser, R.H.1
Puig, J.G.2
Farsang, C.3
Croket, M.4
Li, J.5
van Ingen, H.6
-
81
-
-
39849089447
-
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial
-
Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-99.
-
(2008)
J Hypertens
, vol.26
, pp. 589-599
-
-
Andersen, K.1
Weinberger, M.H.2
Egan, B.3
-
82
-
-
60549087324
-
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide
-
Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-25.
-
(2009)
Circulation
, vol.119
, pp. 417-425
-
-
Schmieder, R.E.1
Philipp, T.2
Guerediaga, J.3
-
83
-
-
67649763542
-
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, doubleblind trial
-
Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, doubleblind trial. J Hypertens 2009; 27: 1493-501.
-
(2009)
J Hypertens
, vol.27
, pp. 1493-1501
-
-
Schmieder, R.E.1
Philipp, T.2
Guerediaga, J.3
Gorostidi, M.4
Bush, C.5
Keefe, D.L.6
-
84
-
-
33845366982
-
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
-
Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-26.
-
(2007)
J Hypertens
, vol.25
, pp. 217-226
-
-
Villamil, A.1
Chrysant, S.G.2
Calhoun, D.3
-
85
-
-
0019403812
-
Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension
-
Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981; 12: 387-92.
-
(1981)
Br J Clin Pharmacol
, vol.12
, pp. 387-392
-
-
Lijnen, P.1
Fagard, R.2
Staessen, J.3
Amery, A.4
-
86
-
-
38349116979
-
-
[Last assessed August 17, 2009]
-
FDA Approves New Drug Treatment for High Blood Pressure. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108862.htm.[Last assessed August 17, 2009].
-
FDA Approves New Drug Treatment For High Blood Pressure
-
-
-
87
-
-
66149089653
-
Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone
-
Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009; 25: 903-10.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 903-910
-
-
Blumenstein, M.1
Romaszko, J.2
Calderon, A.3
-
89
-
-
36248931230
-
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy
-
Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9: 742-50.
-
(2007)
J Clin Hypertens (Greenwich)
, vol.9
, pp. 742-750
-
-
Drummond, W.1
Munger, M.A.2
Rafique, E.M.3
Maboudian, M.4
Khan, M.5
Keefe, D.L.6
-
91
-
-
0033004196
-
Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects
-
Blumenfeld JD, Sealey JE, Mann SJ, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12: 451-9.
-
(1999)
Am J Hypertens
, vol.12
, pp. 451-459
-
-
Blumenfeld, J.D.1
Sealey, J.E.2
Mann, S.J.3
-
92
-
-
56749085787
-
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1
-
Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. J Renin Angiotensin Aldosterone Syst 2008; 9: 163-75.
-
(2008)
J Renin Angiotensin Aldosterone Syst
, vol.9
, pp. 163-175
-
-
Dietz, R.1
Dechend, R.2
Yu, C.M.3
-
93
-
-
77952907194
-
-
[Last assessed August 17, 2009]
-
Combined Renin Inhibition/Beta-Blockade. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00627861[Last assessed August 17, 2009].
-
Combined Renin Inhibition/Beta-Blockade
-
-
-
94
-
-
25444454353
-
Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats
-
Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats. Hypertension 2005; 46: 569-76.
-
(2005)
Hypertension
, vol.46
, pp. 569-576
-
-
Pilz, B.1
Shagdarsuren, E.2
Wellner, M.3
-
95
-
-
46449118638
-
Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats
-
Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-6.
-
(2008)
Hypertension
, vol.52
, pp. 130-136
-
-
Feldman, D.L.1
Jin, L.2
Xuan, H.3
-
96
-
-
61349170589
-
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
-
Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-7.
-
(2009)
Circulation
, vol.119
, pp. 530-537
-
-
Solomon, S.D.1
Appelbaum, E.2
Manning, W.J.3
-
97
-
-
79958249630
-
The Aliskiren Observation of Heart Failure Treatment. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure
-
McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD; for the Aliskiren Observation of Heart Failure Treatment. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 17-24
-
-
McMurray, J.J.V.1
Pitt, B.2
Latini, R.3
Maggioni, A.P.4
Solomon, S.D.5
-
98
-
-
44849114597
-
Aliskiren combined with losartan in type 2 diabetes and nephropathy
-
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46.
-
(2008)
N Engl J Med
, vol.358
, pp. 2433-2446
-
-
Parving, H.H.1
Persson, F.2
Lewis, J.B.3
Lewis, E.J.4
Hollenberg, N.K.5
-
99
-
-
70349690296
-
Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria
-
Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 2009; 30: 1873-9.
-
(2009)
Diabetes Care
, vol.30
, pp. 1873-1879
-
-
Persson, F.1
Rossing, P.2
Reinhard, H.3
-
101
-
-
65249182083
-
Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design
-
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-71.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 1663-1671
-
-
Parving, H.H.1
Brenner, B.M.2
McMurray, J.J.3
-
105
-
-
57449100853
-
Aliskiren accumulates in Renin secretory granules and binds plasma prorenin
-
Krop M, Garrelds IM, de Bruin RJ, et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008; 52: 1076-83.
-
(2008)
Hypertension
, vol.52
, pp. 1076-1083
-
-
Krop, M.1
Garrelds, I.M.2
de Bruin, R.J.3
-
106
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
Bosch, J.4
Davies, R.5
Dagenais, G.6
-
107
-
-
33746863179
-
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials
-
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-8.
-
(2006)
Lancet
, vol.368
, pp. 581-588
-
-
Dagenais, G.R.1
Pogue, J.2
Fox, K.3
Simoons, M.L.4
Yusuf, S.5
-
108
-
-
42349086752
-
Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine
-
Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-11.
-
(2008)
Hypertension
, vol.51
, pp. 1306-1311
-
-
Nussberger, J.1
Aubert, J.F.2
Bouzourene, K.3
Pellegrin, M.4
Hayoz, D.5
Mazzolai, L.6
-
109
-
-
40549106756
-
Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice
-
Lu H, Rateri DL, Feldman DL, Jr, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-93.
-
(2008)
J Clin Invest
, vol.118
, pp. 984-993
-
-
Lu, H.1
Rateri, D.L.2
Feldman Jr., D.L.3
-
110
-
-
10344249378
-
Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system
-
Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61.
-
(2004)
J Hypertens
, vol.22
, pp. 2253-2261
-
-
Kurtz, T.W.1
Pravenec, M.2
-
111
-
-
51549101894
-
Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats
-
Rizzoni D, Pasini E, Flati V, et al. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens 2008; 26: 1595-601.
-
(2008)
J Hypertens
, vol.26
, pp. 1595-1601
-
-
Rizzoni, D.1
Pasini, E.2
Flati, V.3
-
112
-
-
77952947713
-
Are the pleiotropic effects of telmisartan clinically relevant?
-
Rizos CV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effects of telmisartan clinically relevant? Curr Pharm Des 2009; 63: 1308-13.
-
(2009)
Curr Pharm Des
, vol.63
, pp. 1308-1313
-
-
Rizos, C.V.1
Elisaf, M.S.2
Liberopoulos, E.N.3
-
113
-
-
54349098473
-
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat
-
Habibi J, Whaley-Connell A, Hayden MR, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149: 5643-53.
-
(2008)
Endocrinology
, vol.149
, pp. 5643-5653
-
-
Habibi, J.1
Whaley-Connell, A.2
Hayden, M.R.3
-
114
-
-
66649091226
-
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression
-
Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-8.
-
(2009)
Endocrinology
, vol.150
, pp. 2561-2568
-
-
Lastra, G.1
Habibi, J.2
Whaley-Connell, A.T.3
-
116
-
-
0033288410
-
Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial
-
The Captopril Prevention Project (CAPP) Study Group
-
Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group. Curr Hypertens Rev 1999; 1: 466-7.
-
(1999)
Curr Hypertens Rev
, vol.1
, pp. 466-467
-
-
-
117
-
-
0037160968
-
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlof, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
-
118
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
-
119
-
-
38949084591
-
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-60.
-
(2008)
Diabetes Care
, vol.31
, pp. 353-360
-
-
Black, H.R.1
Davis, B.2
Barzilay, J.3
-
120
-
-
33749590988
-
Effect of ramipril on the incidence of diabetes
-
Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62.
-
(2006)
N Engl J Med
, vol.355
, pp. 1551-1562
-
-
Bosch, J.1
Yusuf, S.2
Gerstein, H.C.3
-
121
-
-
29144477713
-
Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures
-
Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
-
(2006)
Curr Drug Targets
, vol.7
, pp. 211-228
-
-
Liberopoulos, E.N.1
Tsouli, S.2
Mikhailidis, D.P.3
Elisaf, M.S.4
-
122
-
-
24644510705
-
Long-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension
-
Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-46.
-
(2005)
Circulation
, vol.112
, pp. 1339-1346
-
-
Bosch, J.1
Lonn, E.2
Pogue, J.3
Arnold, J.M.4
Dagenais, G.R.5
Yusuf, S.6
-
123
-
-
52949093903
-
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
-
Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008; 156: 623-32.
-
(2008)
Am Heart J
, vol.156
, pp. 623-632
-
-
Califf, R.M.1
Boolell, M.2
Haffner, S.M.3
-
124
-
-
33947182655
-
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension
-
Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-63.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1157-1163
-
-
Oh, B.H.1
Mitchell, J.2
Herron, J.R.3
Chung, J.4
Khan, M.5
Keefe, D.L.6
-
125
-
-
75149195876
-
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study
-
Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
-
(2010)
J Hum Hypertens
, vol.24
, pp. 93-103
-
-
Palatini, P.1
Jung, W.2
Shlyakhto, E.3
Botha, J.4
Bush, C.5
Keefe, D.L.6
-
126
-
-
27544463207
-
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis
-
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.
-
(2005)
Lancet
, vol.366
, pp. 1545-1553
-
-
Lindholm, L.H.1
Carlberg, B.2
Samuelsson, O.3
-
127
-
-
33748650250
-
New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
-
Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006; 7: 61-3.
-
(2006)
J Renin Angiotensin Aldosterone Syst
, vol.7
, pp. 61-63
-
-
Sever, P.1
-
128
-
-
35948950676
-
Plasma renin and risk of cardiovascular disease and mortality: The Framingham Heart Study
-
Parikh NI, Gona P, Larson MG, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007; 28: 2644-52.
-
(2007)
Eur Heart J
, vol.28
, pp. 2644-2652
-
-
Parikh, N.I.1
Gona, P.2
Larson, M.G.3
-
129
-
-
33845709506
-
Multiple biomarkers for the prediction of first major cardiovascular events and death
-
Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
-
(2006)
N Engl J Med
, vol.355
, pp. 2631-2639
-
-
Wang, T.J.1
Gona, P.2
Larson, M.G.3
-
130
-
-
34247644329
-
Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness
-
Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-97.
-
(2007)
Am J Hypertens
, vol.20
, pp. 587-597
-
-
Sealey, J.E.1
Laragh, J.H.2
-
131
-
-
34548442794
-
The difficult conception, birth and delivery of a renin inhibitor: Controversies around aliskiren
-
Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25: 1775-82.
-
(2007)
J Hypertens
, vol.25
, pp. 1775-1782
-
-
Menard, J.1
Azizi, M.2
-
132
-
-
42049104395
-
The renin rise with aliskiren: It's simply stoichiometry
-
Danser AH, Charney A, Feldman DL, Nussberger J, Fisher N, Hollenberg N. The renin rise with aliskiren: it's simply stoichiometry. Hypertension 2008; 51: e27-8.
-
(2008)
Hypertension
, vol.51
-
-
Danser, A.H.1
Charney, A.2
Feldman, D.L.3
Nussberger, J.4
Fisher, N.5
Hollenberg, N.6
-
133
-
-
37349091464
-
Interpretation of plasma renin concentration in patients receiving aliskiren therapy
-
Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51: 15-8.
-
(2008)
Hypertension
, vol.51
, pp. 15-18
-
-
Campbell, D.J.1
-
134
-
-
44849107992
-
Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells
-
Batenburg WW, de Bruin RJ, van Gool JM, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1151-7.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, pp. 1151-1157
-
-
Batenburg, W.W.1
de Bruin, R.J.2
van Gool, J.M.3
-
135
-
-
65949116587
-
Activity assays and immunoassays for plasma Renin and prorenin: Information provided and precautions necessary for accurate measurement
-
Campbell DJ, Nussberger J, Stowasser M, et al. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55: 867-77.
-
(2009)
Clin Chem
, vol.55
, pp. 867-877
-
-
Campbell, D.J.1
Nussberger, J.2
Stowasser, M.3
-
136
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
-
(2008)
N Engl J Med
, vol.358
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
137
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
-
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
-
(2008)
Lancet
, vol.372
, pp. 547-553
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
-
138
-
-
34648814214
-
Dual inhibition of the renin system by aliskiren and valsartan
-
Oparil S, Yarows SA, Patel S, Zhang J, Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007; 370: 1126-7.
-
(2007)
Lancet
, vol.370
, pp. 1126-1127
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Zhang, J.4
Satlin, A.5
-
139
-
-
69849114573
-
Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind study
-
Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25: 1288-302.
-
(2008)
Adv Ther
, vol.25
, pp. 1288-1302
-
-
Yarows, S.A.1
Oparil, S.2
Patel, S.3
Fang, H.4
Zhang, J.5
-
140
-
-
0030806988
-
Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
-
Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
-
(1997)
Circulation
, vol.96
, pp. 509-516
-
-
Tsutamoto, T.1
Wada, A.2
Maeda, K.3
-
141
-
-
67650451498
-
Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the national kidney foundation and the us food and drug administration
-
Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national kidney foundation and the us food and drug administration. Am J Kidney Dis 2009; 54: 205-26.
-
(2009)
Am J Kidney Dis
, vol.54
, pp. 205-226
-
-
Levey, A.S.1
Cattran, D.2
Friedman, A.3
-
142
-
-
69249202278
-
Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively
-
Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens 2009; 22: 954-7.
-
(2009)
Am J Hypertens
, vol.22
, pp. 954-957
-
-
Stanton, A.V.1
Dicker, P.2
O'Brien, E.T.3
|